ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0251

Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study

Jie Wei1, Hyon K. Choi2, Nicola Dalbeth3, Xiaoxiao Li4, Changjun Li5, Chao Zeng6, Guanghua Lei6 and Yuqing Zhang7, 1Health Management Center, Xiangya Hospital Central South University, Changsha, China, 2Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 3University of Auckland, Auckland, New Zealand, 4Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 6Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 7Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Epidemiology, gout, Mortality, population studies, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however, their impact on recurrent flares is unknown. We aimed to examine the relation of SGLT2i vs. active comparators (i.e., glucagon-like peptide-1 receptor agonist or dipeptidyl peptidase 4 inhibitors) to the risk of recurrent gout flares, the first recurrent gout flare, and all-cause mortality among patient with gout and type 2 diabetes.

Methods: Using IQVIA Medical Research Database in the United Kingdom, we identified initiators of SGLT2i and active comparators among gout patients with type 2 diabetes from a United Kingdom primary care database. We conducted cohort studies to examine the relation of SGLT2i vs. active comparators to the risk of recurrent flares, the first recurrent flare, and all-cause mortality using either Poisson regression or Cox-proportional hazards model with propensity score overlap weighting. The primary outcome was the number of recurrent gout flares that were ascertained using recorded codes and prescriptions records. Secondary outcomes were the first recurrent gout flare and all-cause mortality.

Results: During 17,729 person-years of follow-up, 318 recurrent flares occurred in the 1,548 initiators of SGLT2i and 1,714 in the 4,383 initiators of active comparators, respectively. The relative rate of the recurrent flares of SGLT2i vs. active comparators was 0.79 (95%CI: 0.64 to 0.96). Similar results were observed in the relation of SGLT2i to the risk of number of recurrent flares when compared with DPP-4i or GLP-1 receptor agonist, respectively (Table 1). The rate difference (RD) and hazard ratio (HR) of the first recurrent flare for SGLT2i vs. active comparators were -9.2 (95%CI: -18.0 to -0.4) per 1000 person-years and 0.80 (95%CI: 0.64 to 0.98), respectively. All-cause mortality per 1000 person-years was 18.5 for SGLT2i and 24.2 for active comparators, with RD and HR being -5.8 (95%CI: -10.1 to -1.5) per 1000 person-years and 0.72 (95%CI: 0.53 to 0.97) (Table 2).

Conclusion: SGLT2i were associated with a lower risk of recurrent gout flares and mortality than their active comparators in patients with gout and type 2 diabetes. Our findings suggested that SGLT2i have a potential to reduce the burden of recurrent gout flares and narrow the mortality gap between patients with gout and the general population.

Supporting image 1

Table 1. Risk of recurrent gout flares according to initiation of either SGLT2i or active comparators among patients with gout and type 2 diabetes

Supporting image 2

Table 2. Risk of the first recurrent gout flares and all-cause mortality according to initiation of either SGLT2i or active comparators among patients with gout and type 2 diabetes


Disclosures: J. Wei: None; H. Choi: Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2; N. Dalbeth: Arthrosi, 2, AstraZeneca, 2, Dyve Biosciences, 2, Hikma, 6, Horizon, 2, JW Pharmaceutical Corporation, 2, LG, 2, Novartis, 6, Novotech, 5, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Unlocked Labs, 2; X. Li: None; C. Li: None; C. Zeng: None; G. Lei: None; Y. Zhang: None.

To cite this abstract in AMA style:

Wei J, Choi H, Dalbeth N, Li X, Li C, Zeng C, Lei G, Zhang Y. Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sodium-glucose-cotransporter-2-inhibitor-initiation-risk-of-recurrent-gout-flares-and-mortality-in-patients-with-gout-and-type-2-diabetes-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sodium-glucose-cotransporter-2-inhibitor-initiation-risk-of-recurrent-gout-flares-and-mortality-in-patients-with-gout-and-type-2-diabetes-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology